Democratic Republic of the Congo & Mapp Biopharmaceutical

Democratic Republic of the Congo: The Democratic Republic of the Congo is experiencing an ongoing outbreak of the Bundibugyo strain of Ebola, leading to the World Health Organization's recommendations for experimental treatments and vaccines.

Mapp Biopharmaceutical: Mapp Biopharmaceutical developed MBP134, one of the experimental treatments prioritized by the World Health Organization for the Bundibugyo strain of Ebola.

Democratic Republic of the Congo: Epicenter of the outbreak; government struggling to contain spread amid conflict and mistrust; economic and social disruption.

Mapp Biopharmaceutical: Supplying experimental MBP134 antibody for trials; potential positive impact if treatment proves effective.

Democratic Republic of the Congo: The Democratic Republic of the Congo>>> is the epicenter of the current Ebola outbreak, with hundreds of suspected cases and deaths, facing significant challenges in containment due to conflict, weak health infrastructure, and public mistrust.

Mapp Biopharmaceutical: Mapp Biopharmaceutical>>>'s pan-ebolavirus antibody drug, MBP134, is a potential candidate for clinical trials against the Uganda — Bundibugyo strain, with development backed by BARDA.